Impax Laboratories Company Profile (NASDAQ:IPXL)

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

Impax Laboratories, Inc. (NASDAQ:IPXL) posted its quarterly earnings data on Wednesday, August, 9th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. Impax Laboratories's quarterly revenue was up 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.21 earnings per share. View Impax Laboratories' Earnings History.

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Impax Laboratories.

Impax Laboratories updated its FY17 earnings guidance on Wednesday, August, 9th. The company provided EPS guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.66.

14 brokerages have issued 12-month price objectives for Impax Laboratories' shares. Their forecasts range from $10.00 to $26.00. On average, they expect Impax Laboratories' share price to reach $19.57 in the next twelve months. View Analyst Ratings for Impax Laboratories.

Here are some recent quotes from research analysts about Impax Laboratories stock:

• 1. Cantor Fitzgerald analysts commented, "We are raising our PT for IPXL shares to $25 from $20, and maintaining our Overweight rating for the stock. The increase in our PT is driven by multiple expansion. After speaking to the company, we believe that the company’s execution of its stated business objectives continues to meet or beat our expectations." (9/6/2017)
• 2. According to Zacks Investment Research, "Impax’s Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. However, the epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. The company is also taking steps to reduce costs and improve efficiencies, which is estimated to save a total of $130 million by the end of 2019. However, the company’s 2017 earnings guidance is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to hurt revenues. Moreover, the company’s manufacturing facilities had been hampered by quality control issues since 2011 and an inspection had even delayed Rytary’s approval. Impax is also involved in a patent litigation regarding approval of generic version of Rytary. Estimates have been mostly stable ahead of the Q2 results. Impax does not have an impressive record of earnings surprises in the recent quarters." (7/24/2017)
• 3. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
• 4. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)

Impax Laboratories saw a increase in short interest in August. As of August 15th, there was short interest totalling 8,583,256 shares, an increase of 25.7% from the July 31st total of 6,830,967 shares. Based on an average daily volume of 2,654,227 shares, the short-interest ratio is currently 3.2 days. Approximately 11.9% of the company's shares are sold short.

Some companies that are related to Impax Laboratories include Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), AKCEA THERAPEUT (AKCA), Emergent Biosolutions (EBS), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Teligent (TLGT), Corium International (CORI) and Tetraphase Pharmaceuticals (TTPH).

Impax Laboratories' management team includes the folowing people:

• Robert L. Burr, Independent Chairman of the Board
• Paul M. Bisaro, President, Chief Executive Officer, Director
• Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
• Douglas S. Boothe, President - Generics Division
• Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
• Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
• Jeffrey D. Nornhold, Senior Vice President - Technical Operations
• J. Kevin Buchi, Director
• Janet S. Vergis, Director
• Leslie Z. Benet Ph.D., Independent Director

Impax Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (9.63%), Vanguard Group Inc. (9.53%), SHANGHAI FOSUN PHARMACEUTICAL (GROUP) COMPANY ., LTD. (5.19%), Dimensional Fund Advisors LP (4.53%), Frontier Capital Management Co. LLC (2.21%) and Balyasny Asset Management LLC (1.41%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Federated Investors Inc. PA, Thrivent Financial For Lutherans, Canada Pension Plan Investment Board, Quantitative Investment Management LLC, Penn Capital Management Co. Inc., OxFORD Asset Management LLP and Icon Advisers Inc. Co.. View Insider Buying and Selling for Impax Laboratories.

Impax Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Balyasny Asset Management LLC, Stifel Financial Corp, Dimensional Fund Advisors LP, Vanguard Group Inc., Nexthera Capital LP, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Impax Laboratories.

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Impax Laboratories stock can currently be purchased for approximately $20.95.